A Safety and Efficacy Study of Eltrombopag in Subjects With AML

Acute Leukaemia Clinical Trial

Official title:
A Randomized, Blinded, Placebo-Controlled, Dose Finding Study to Assess the Safety and Efficacy of the Oral Thrombopoietin Receptor Agonist, Eltrombopag, Administered to Subjects With Acute Myelogenous Leukaemia (AML) Receiving Induction Chemotherapy

Status Completed

Clinical Trial Summary

The purpose of this randomized, blinded, placebo-controlled study was to provide clinical safety and exploratory efficacy data on the use of Eltrombopag in adult subjects with Acute Myeloid Leukemia (AML) receiving standard induction chemotherapy with daunorubicin plus cytarabine. A minimum of 120 evaluable subjects newly diagnosed with AML was stratified by antecedent malignant hematologic disorder and age.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01890746
Study type	Interventional
Source	Novartis
Contact
Status	Completed
Phase	Phase 2
Start date	September 5, 2013
Completion date	January 25, 2017

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT00993538` - Leukemia Cell Cultures for Research of New Anti-Cancer Therapies	N/A
Completed	`NCT02058888` - Amplification and Selection of Antimicrobial Resistance in the Intestine	N/A
Completed	`NCT01521611` - Targeted Radiotherapy in HSCT for Poor Risk Haematological Malignancy	Phase 1/Phase 2
Withdrawn	`NCT00570999` - Palifermin After Haploidentical PBSCT	Phase 2
Recruiting	`NCT02123836` - Natural Killer Cells in Acute Leukaemia and Myelodysplastic Syndrome	Phase 1
Completed	`NCT00795132` - Hematopoietic Cell Transplantation for Pediatric Patients With Hematologic Malignancies	Phase 2